Ovid Therapeutics Inc. announced initiations of the Phase 2 ELEKTRA and ARCADE trials for OV935/TAK-935 in pediatric patients with rare epilepsies. The company reports that the first patient has been randomized to receive either OV935 or placebo in the ELEKTRA trial, and that patient screening is underway for the ARCADE trial.
September 24, 2018
October 22, 2019
CURE Discovery: Understanding and Treating NMDA Receptor-Associated Epilepsy
Researchers are studying whether off-label treatment with certain FDA-approved drugs can improve seizure control for individuals who have a GRIN mutation and whose epilepsy is caused by over-activation of NMDA-R.